Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Gembrax then FOLFIRINOX followed by adaptive MRI-guided stereotactic radiotherapy in locally advanced pancreatic adenocarcinoma
2020-002517-18Phase 2Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jul 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel, irinotecan, oxaliplatin, fluorouracil and 1 more in pancreatic adenocarcinoma (PDAC), sponsored by Institut du Cancer de Montpellier. Started Jul 2020; status: active.
02
Drugs
gemcitabinepaclitaxelirinotecanoxaliplatinfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2020-002517-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002517-18.